Evidence map›Paper›PMID 38388896›Full record

ReviewNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2024

Novel and experimental therapeutics for the management of motor and non-motor Parkinsonian symptoms.

Inam Ullah, Xin Wang, Hongyu Li

Abstract readReview
PubMed Publisher
In one paragraph

Review in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Nutritional and dietary clinical trials for Parkinson's disease: a narrative review.Journal of neural transmission (Vienna, Austria : 1996) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Inam UllahSchool of Life Sciences, Lanzhou University, Lanzhou, China.
Xin WangSchool of Pharmacy, Lanzhou University, Lanzhou, China. wx@lzu.edu.cn.ORCID http://orcid.org/0009-0001-8618-0510
Hongyu LiSchool of Life Sciences, Lanzhou University, Lanzhou, China. lihy@lzu.edu.cn.

Funding

Natural Science Foundation of Gansu Province 20JR10RA602Science and Technology Department of Gansu Province 23ZDFA013-4
6 · The paper itself

Abstract

backgroundBoth motor and non-motor symptoms of Parkinson's disease (PD) have a substantial detrimental influence on the patient's quality of life. The most effective treatment remains oral levodopa. All currently known treatments just address the symptoms; they do not completely reverse the condition. METHODOLOGY: In order to find literature on the creation of novel treatment agents and their efficacy for PD patients, we searched PubMed, Google Scholar, and other online libraries.

resultsAccording to the most recent study on Parkinson's disease (PD), a great deal of work has been done in both the clinical and laboratory domains, and some current scientists have even been successful in developing novel therapies for PD patients.

conclusionThe quality of life for PD patients has increased as a result of recent research, and numerous innovative medications are being developed for PD therapy. In the near future, we will see positive outcomes regarding PD treatment.

Indexed as

Antiparkinson AgentsParkinson DiseaseHumansQuality of LifeAntiparkinson AgentsClinical trials of novel moleculesNew drug developmentParkinson’s diseasePD pathology

Identifiers

PMID38388896

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.